Coagulation factor XIIIa is inactivated by plasmin

Blood

Volumn 126, Issue 20, 2015, Pages 2329-2337

  Hur, Woosuk S ^a   Mazinani, Nima ^a   Lu, X J David ^a   Britton, Heidi M ^a   Byrnes, James R ^b   Wolberg, Alisa S ^b   Kastrup, Christian J ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 13A; ENZYME PRECURSOR; FIBRINOGEN; PLASMIN; TISSUE PLASMINOGEN ACTIVATOR; BLOOD CLOTTING FACTOR 13;

AMMONIA FORMATION; ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOTTING; DEGRADATION; ENZYME METABOLISM; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN DEGRADATION; THROMBOCYTE ACTIVATION; WESTERN BLOTTING; YOUNG MODULUS; CHEMISTRY; FIBRINOLYSIS; HUMAN; METABOLISM; PHYSIOLOGY;

FACTOR XIII; FIBRINOLYSIN; FIBRINOLYSIS; HUMANS; PROTEOLYSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84949009516     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-07-650713     Document Type: Article

References (26)

1. Muszbek L, Bereczky Z, Bagoly Z, Komáromi I, Katoná E. Factor XIII: a coagulation factor with multiple plasmatic and cellular functions. Physiol Rev. 2011;91(3):931-972.
2. Katona E, Pénzes K, Csapó A, et al. Interaction of factor XIII subunits. Blood. 2014;123(11): 1757-1763.
3. Siebenlist KR, Meh DA, Mosesson MW. Plasma factor XIII binds specifically to fibrinogen molecules containing gamma chains. Biochemistry. 1996;35(32):10448-10453.
4. Takahashi N, Takahashi Y, Putnam FW. Primary structure of blood coagulation factor XIIIa (fibrinoligase, transglutaminase) from human placenta. Proc Natl Acad Sci USA. 1986;83(21): 8019-8023.
5. Bagoly Z, Haramura G, Muszbek L. Downregulation of activated factor XIII by polymorphonuclear granulocyte proteases within fibrin clot. Thromb Haemost. 2007;98(2):359-367.
6. Weisel JW, Medved L. The structure and function of the alpha C domains of fibrinogen. Ann N Y Acad Sci. 2001;936:312-327.
7. Rider DM, McDonagh J. Resistance of factor XIII to degradation or activation by plasmin. Biochim Biophys Acta. 1981;675(2):171-177.
8. Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs. 1999; 57(6):1005-1032.
9. Aleman MM, Byrnes JR, Wang JG, et al. Factor XIII activity mediates red blood cell retention in venous thrombi. J Clin Invest. 2014;124(8): 3590-3600.
10. Hsu JL, Huang SY, Chow NH, Chen SH. Stable-isotope dimethyl labeling for quantitative proteomics. Anal Chem. 2003;75(24):6843-6852.
11. Foster LJ, De Hoog CL, Mann M. Unbiased quantitative proteomics of lipid rafts reveals high specificity for signaling factors. Proc Natl Acad Sci USA. 2003;100(10):5813-5818.
12. Rappsilber J, Ishihama Y, Mann M. Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. Anal Chem. 2003;75(3):663-670.
13. Fox BA, Yee VC, Pedersen LC, et al. Identification of the calcium binding site and a novel ytterbium site in blood coagulation factor XIII by x-ray crystallography. J Biol Chem. 1999;274(8): 4917-4923.
14. Stieler M, Weber J, Hils M, et al. Structure of active coagulation factor XIII triggered by calcium binding: basis for the design of next-generation anticoagulants. Angew Chem Int Ed Engl. 2013; 52(45):11930-11934.
15. Komorowicz E, Kolev K, Machovich R. Fibrinolysis with des-kringle derivatives of plasmin and its modulation by plasma protease inhibitors. Biochemistry. 1998;37(25):9112-9118.
16. Mitchell JL, Lionikiene AS, Fraser SR, Whyte CS, Booth NA, Mutch NJ. Functional factor XIII-A is exposed on the stimulated platelet surface. Blood. 2014;124(26):3982-3990.
17. Kopéc M, Latallo ZS, Stahl M, Wegrzynowicz Z. The effect of proteolytic enzymes on fibrin stabilizing factor. Biochim Biophys Acta. 1969; 181(2):437-445.
18. Bucay I, O'Brien ET III, Wulfe SD, et al. Physical determinants of fibrinolysis in single fibrin fibers. PLoS One. 2015;10(2):e0116350.
19. Schaller J, Gerber SS. The plasmin-antiplasmin system: structural and functional aspects. Cell Mol Life Sci. 2011;68(5):785-801.
20. Inbal A, Oldenburg J, Carcao M, Rosholm A, Tehranchi R, Nugent D. Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency. Blood. 2012;119(22):5111-5117.
21. Adams HP Jr, Leira EC, Torner JC, et al; AbESTT-II Investigators. Treating patients with 'wake-up' stroke: the experience of the AbESTT-II trial. Stroke. 2008;39(12):3277-3282.
22. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke. 1997;28(11): 2109-2118.
23. Cannon CP, McCabe CH, Gibson CM, et al. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation. 1997;95(2):351-356.
24. Acheampong P, Ford GA. Pharmacokinetics of alteplase in the treatment of ischaemic stroke. Expert Opin Drug Metab Toxicol. 2012;8(2): 271-281.
25. Kahr WH, Zheng S, Sheth PM, et al. Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator. Blood. 2001;98(2):257-265.
26. Thelwell C, Longstaff C. The regulation by fibrinogen and fibrin of tissue plasminogen activator kinetics and inhibition by plasminogen activator inhibitor 1. J Thromb Haemost. 2007; 5(4):804-811.